Janus Henderson Investors
Janus Henderson Investors is an asset manager that helps their clients achieve their financial goals.
Business Model:
Revenue: $2.4B
Employees: 1,001-5,000
Rankings
Industries / Tags:
Detailed Janus Henderson Investors Information
Geographic Data
Address: 201 Bishopsgate
City: London
State: england
Zip: EC2M 3AE
Country: GB
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
225,954Website Global Rank
301,920Website Monthly Traffic
Twitter Followers
Description
Janus Henderson Group plc is a global asset management group. Janus Henderson Investors exists to help clients achieve their long-term financial goals. We currently manage £265.3bn (US$371.9bn) and employ more than 2000 members of staff worldwide (as at 31 March 2018).
Contact Phone:
Contact Email:
Janus Henderson Investors went public on 6/2/2017 on the NYSE
Listed Exchange:
NYSE
IPO Date:
6/2/2017
Ticker Symbol:
JHG
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2023 | Carmot Therapeutics | Series E | 0 |
| 3/2021 | Amunix | Series B | 117M |
| 12/2021 | Grab | Post-IPO Equity | 0 |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 1/2022 | Curevo | Series A | 0 |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 2/2021 | Inivata | Series C | 35M |
| 1/2018 | BioNTech | Series A | 270M |
| 6/2022 | Elektrofi | Series B | 0 |
| 2/2022 | Parse Biosciences | Series B | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 12/2019 | FORMA Therapeutics | Series D | 100M |
| 2/2021 | HemoShear Therapeutics | Series A | 40M |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 2/2023 | Via | Venture Round | 0 |
| 7/2020 | Cybin | Series B | 0 |
| 12/2020 | Apartment List | Series D | 60M |
| 1/2021 | New Amsterdam Pharma | Series A | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 2/2021 | Viracta Therapeutics | Post-IPO Equity | 65M |
| 2/2022 | Loadsmart | Series D | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 7/2021 | Owlet Baby Care | Post-IPO Equity | 130M |
| 11/2020 | Decibel Therapeutics | Series D | 82.2M |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 5/2021 | Magenta Therapeutics | Post-IPO Equity | 86.4M |
| 4/2023 | HeartFlow | Series F | 0 |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 7/2020 | Olema Oncology | Series B | 54M |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 8/2020 | Freenome | Series C | 270M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 12/2020 | SomaLogic | Series A | 0 |
| 1/2019 | Sojournix | Series C | 44M |
| 2/2021 | Shoreline Biosciences | Series A | 0 |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 11/2021 | Via | Series G | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 11/2020 | QuantumScape | Post-IPO Equity | 500M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 6/2020 | Everest Medicines | Series C | 310M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 9/2021 | Attralus | Series B | 116M |
| 10/2021 | Wallbox | Post-IPO Equity | 100M |
| 2/2019 | Aprea | Series C | 5.7M |
| 8/2021 | Xos Trucks | Post-IPO Equity | 220M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 10/2021 | ShouTi | Series B | 0 |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 7/2019 | IGM Biosciences | Series C | 102M |
| 8/2022 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 4/2022 | IntelyCare | Series C | 0 |
| 2/2022 | Inspirato | Post-IPO Equity | 100M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 12/2022 | Entact Bio | Series A | 81M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 10/2021 | PharmEasy | Venture Round | 0 |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 6/2021 | Element Biosciences | Series C | 276M |
| 10/2021 | Cedilla Therapeutics | Series B | 0 |
| 6/2020 | Shattuck Labs | Series B | 0 |
| 9/2020 | Galecto | Series D | 0 |
| 12/2021 | P3 Health Partners | Post-IPO Equity | 200M |
| 3/2021 | Caribou Biosciences | Series C | 115M |
| 4/2021 | Janux Therapeutics | Series B | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 2/2021 | Cyteir Therapeutics | Series C | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 4/2021 | Icosavax | Series B | 0 |
| 11/2022 | Curevo | Series A | 0 |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 11/2021 | Quell Therapeutics | Series B | 0 |
| 3/2023 | Bicara Therapeutics | Series B | 0 |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 7/2020 | BioAtla | Series D | 0 |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 12/2017 | Bigfoot Biomedical | Series B | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 2/2022 | Magnolia Medical Technologies | Venture Round | 0 |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 3/2021 | Tyra Biosciences | Series B | 106M |
| 6/2021 | Synthekine | Series B | 0 |
| 10/2021 | Structure Therapeutics | Series B | 0 |
| 3/2021 | DTx Pharma | Series B | 100M |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 7/2020 | VelosBio | Series B | 137M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 8/2021 | CCC Information Services | Post-IPO Equity | 150M |
| 1/2020 | Bigfoot Biomedical | Series C | 0 |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 10/2020 | Olema Oncology | Series C | 85M |
| 4/2021 | ValenzaBio | Series A | 0 |
| 7/2020 | Annexon Biosciences | Series C | 100M |
| 6/2022 | Elektrofi | Series B | 0 |
| 4/2022 | IntelyCare | Series C | 0 |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 2/2022 | Magnolia Medical Technologies | Venture Round | 0 |
| 2/2022 | Inspirato | Post-IPO Equity | 0 |
| 2/2022 | Parse Biosciences | Series B | 0 |
| 2/2022 | Loadsmart | Series D | 0 |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 1/2022 | Curevo | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
